Studying Genes Using Cord Blood and Placenta Samples From Relatively Healthy Newborns and Samples From Younger Patients With Wilms Tumor
NCT ID: NCT01576211
Last Updated: 2016-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research trial studies cord blood and placenta tissue from newborns, and tumor tissue samples from patients with Wilms tumor.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying Biomarkers in Samples From Younger Patients With Wilms Tumor
NCT01576198
Biomarkers in Tumor Tissue Samples From Young Patients With Very Low Risk Wilms Tumors
NCT01004783
Studying Biomarkers in Samples From Younger Patients With Wilms Tumor
NCT01542333
Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor
NCT01118078
Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor
NCT01314391
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* What is the frequency of loss of imprinting at birth (in the cord blood and placenta) in a relatively healthy birth cohort?
* Does deoxyribonucleic acid (DNA) methylation levels at imprinting genes have a direct association to the gene expression?
OUTLINE: Archived tumor tissue, cord blood, and placenta samples are analyzed for DNA methylation, single nucleotide polymorphism, and gene expression by polymerase chain reaction (PCR), pyrosequencing, and quantitative real-time PCR. Information regarding gender and age of the samples are also collected, if possible.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DNA methylation analysis
RNA analysis
allele-specific oligonucleotide real-time quantitative polymerase chain reaction
gene expression analysis
nucleic acid sequencing
polymorphism analysis
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Wilms tumor tissue samples from Caucasians (fresh or frozen), or DNA and ribonucleic acid (RNA) samples already isolated from patients registered on Children's Oncology Group Wilms tumor protocols
* Normal/control blood samples from matched individuals
* Cord blood/ placenta samples from the Michels lab Epigenetic Birth Cohort
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
21 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Karin Michels, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Dana-Farber/Brigham and Women's Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AREN12B6
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000730596
Identifier Type: OTHER
Identifier Source: secondary_id
AREN12B6
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2012-00726
Identifier Type: REGISTRY
Identifier Source: secondary_id
AREN12B6
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.